Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of apatinib perioperative therapy in locally advanced gastric cancer
ChiCTR2100042520Phase 4Recruiting
- Sponsor
- Shandong Provincial Hospital Affiliated to Shandong First Medical University
- Start
- Jan 2021
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of Rivoceranib in gastric cancer (GC) (2 cohorts), sponsored by Shandong Provincial Hospital Affiliated to Shandong First Medical University. Primary endpoints: Disease-free survival and Overall survival. Started Jan 2021; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on ChiCTR2100042520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100042520.